We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Biliary Tract Cancer

News List

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer prnasia
January 21, 2022
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) ...
Lexicon Completes Safety Review of Telotristat Ethyl in Biliary Tract Cancer americanpharmaceuticalreview
December 30, 2019
Lexicon Pharmaceuticals announced the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer ...
FDA grants Orphan Drug Designation for etoposide toniribate americanpharmaceuticalreview
February 26, 2019
Mundipharma EDO GmbH and Imbrium Therapeutics announced the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.